Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Multi-omics analysis reveals the potential for fermented <i>Cordyceps militaris</i> mushroom substrate in laying hens.

Frontiers in microbiology·2026
Same author

Structural evidence that RNA contributes to polymorphism of tau amyloid fibrils.

iScience·2026
Same author

StrucGAP: a modular, streamlined and traceable data mining platform for structural and site-specific glycoproteomics.

Nature communications·2026
Same author

Profile of David Baker, Demis Hassabis, and John Jumper: 2024 Nobel laureates in chemistry.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

The cGAS-STING pathway and mitochondrial metabolism: from mechanistic insights to therapeutic potential in tumor.

Journal of translational medicine·2026
Same author

CRISPR screens in iPSC-derived neurons reveal principles of tau proteostasis.

Cell·2026
Same journal

Breaking barriers: Enhancing access to dementia clinical trials in the United Kingdom-Insights from the Scientific Advisory Board of the Dame Barbara Windsor Dementia Goals Programme.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

薬物開発

Gregory M Cole1,2,3, Cansheng Zhu1,3, Kapil Manglani3,4

  • 1Veterans Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

新規薬剤CNS11gは、パーキンソン病様症状を有するマウスにおいて運動障害と毒性タンパク質凝集体を効果的に軽減した。この経口治療薬は、αシヌクレインおよびタウオリゴマーに対して安全性と有効性を示し、シヌクレイン症およびアルツハイマー病への希望を提供する。

キーワード:
パーキンソン病αシヌクレインタウオリゴマー神経変性疾患創薬

さらに関連する動画

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

関連する実験動画

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学分野:

  • 神経科学
  • 薬理学
  • 生化学

背景:

  • αシヌクレイン（aSyn）凝集体は、パーキンソン病（PD）およびその他のシヌクレイン症に関与している。
  • 家族性PD変異はaSyn凝集を加速させ、マウスモデルにおいて神経変性および運動機能障害を引き起こす。
  • aSynおよびタウ凝集体はアルツハイマー病（AD）にも見られる。

研究 の 目的:

  • PDのマウスモデルにおけるCNS11gの有効性を評価する。
  • 既存のαシヌクレインおよびタウ線維を解凝集するCNS11gの能力を評価する。
  • 後期疾患における経口CNS11gの安全性および治療可能性を決定する。

主な方法:

  • 24ヶ月齢のヘテロ接合体A53T M83マウスに6週間経口投与でCNS11gを投与した。
  • 脳内CNS11g濃度、運動機能、および可溶性および不溶性aSynおよびタウ凝集体のレベルを測定した。
  • ウェスタンブロットおよび免疫組織化学（ICC）を用いてタンパク質凝集体および神経炎症を定量化した。

主要な成果:

  • 経口投与されたCNS11gは治療域の脳内濃度を達成し、毒性なしに運動機能障害を改善した。
  • CNS11gは脊髄および脳幹における可溶性、高分子量aSyn凝集体およびタウオリゴマーを減少させた。
  • ICCではaSyn沈着の減少が示されたが、生化学的分析では不溶性線維状aSynの減少は確認されなかった。

結論:

  • 後期段階でのCNS11gの経口投与は、運動機能障害および特定のタンパク質オリゴマーの減少において安全性と有効性を示した。
  • この薬は、αシヌクレインおよびタウオリゴマーに対して多面的な中枢神経系活性を示す。
  • 不溶性線維を除去するには、より高用量またはより長期間の投与によるさらなる研究が必要となる可能性がある。